Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Neurocrine Biosciences revenue
Neurocrine Biosciences's revenue is $2.4 billion.
What is Neurocrine Biosciences's revenue?
- Neurocrine Biosciences's revenue growth from 2010 to 2024 is 6,930.54%.
- Neurocrine Biosciences has 400 employees, and the revenue per employee ratio is $5,888,250.
- Neurocrine Biosciences's peak quarterly revenue was $627.7M in 2024(q4).
- Neurocrine Biosciences peak revenue was $2.4B in 2024.
- Neurocrine Biosciences annual revenue for 2023 was 1.9B, 26.76% growth from 2022.
- Neurocrine Biosciences annual revenue for 2024 was 2.4B, 24.81% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Neurocrine Biosciences historical revenue
Neurocrine Biosciences's peak revenue was $2.4B in 2024. The peak quarterly revenue was $627.7M in 2024(q4).
Neurocrine Biosciences's revenue increased from $33.5m in 2010 to $2.4B currently. That's a 6,930.54% change in annual revenue.
Neurocrine Biosciences annual revenue
Neurocrine Biosciences annual revenue over time
| Fiscal year / year | Neurocrine Biosciences revenue |
|---|---|
| 2010 | $33.5M |
| 2011 | $77.4M |
| 2012 | $53.1M |
| 2013 | $2.9M |
| 2015 | $19.8M |
| 2016 | $15.0M |
| 2017 | $161.6M |
| 2018 | $451.2M |
| 2019 | $788.1M |
| 2020 | $1.0B |
| 2021 | $1.1B |
| 2022 | $1.5B |
| 2023 | $1.9B |
| 2024 | $2.4B |
How accurately did Neurocrine Biosciences' revenue projections match actual performance?
Neurocrine Biosciences annual growth
Neurocrine Biosciences saw the greatest revenue growth in 2017, when revenue increased by 977.51%.
Neurocrine Biosciences had the lowest revenue growth in 2013, when revenue changed by -94.51%.
Neurocrine Biosciences annual growth rate over time
| Year | Neurocrine Biosciences growth |
|---|---|
| 2011 | 131%↑ |
| 2012 | -31%↓ |
| 2013 | -95%↓ |
| 2015 | 577%↑ |
| 2016 | -24%↓ |
| 2017 | 978%↑ |
| 2018 | 179%↑ |
| 2019 | 75%↑ |
| 2020 | 33%↑ |
| 2021 | 8%↑ |
| 2022 | 31%↑ |
| 2023 | 27%↑ |
| 2024 | 25%↑ |
Neurocrine Biosciences quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Neurocrine Biosciences quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2011 | - | $12.2M | $41.6M | $11.1M |
| 2012 | $11.3M | $10.6M | $9.4M | $21.9M |
| 2013 | $730,000 | $730,000 | $729,000 | $730,000 |
| 2015 | $19.8M | - | - | - |
| 2016 | $15.0M | - | - | - |
| 2017 | - | $6.3M | $60.8M | $94.5M |
| 2018 | $71.1M | $96.9M | $151.8M | $131.5M |
| 2019 | $138.4M | $183.6M | $222.1M | $244.1M |
| 2020 | $237.1M | $302.4M | $258.5M | $247.9M |
| 2021 | $236.6M | $288.9M | $296.0M | $312.0M |
| 2022 | $310.6M | $378.2M | $387.9M | $412.0M |
| 2023 | $420.4M | $452.7M | $498.8M | $515.2M |
| 2024 | $515.3M | $590.2M | $622.1M | $627.7M |
Neurocrine Biosciences jobs nearby
Do you work at Neurocrine Biosciences?
Did Neurocrine Biosciences meet its revenue projections?
Neurocrine Biosciences financial information
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 400 |
| Date Founded | 1992 |
| Headquarters | San Diego, California |
| Number of Locations | 1 |
| Revenue | $2.4B |
| Net Income | $154,500,000 |
| Gross Proft | $2.3B (2024) |
| PE Ratio | 23.43 |
| Tax Rate | 0.3% |
| Market Capitalization | $8.0B |
| Total Assets | $2,368,700,000 |
| Ticker | NBIX |
Neurocrine Biosciences jobs you might like
Neurocrine Biosciences financing
Neurocrine Biosciences received early financing of $10.0M on 2009-12-17.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $10M | 12/2009 |
Neurocrine Biosciences investors
| Investors | Security type |
|---|---|
| Venrock | Post Ipo Equity |
Neurocrine Biosciences competitors
Neurocrine Biosciences's top competitor, Merck, earned an annual revenue of $64.2B.
Neurocrine Biosciences's smallest competitor is Senomyx with revenue of $26.4M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Regeneron | $85,589 | $14.2B | 9,123 | 349 |
| Amgen | $93,349 | $33.4B | 22,000 | 561 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 583 |
| Merck | $90,328 | $64.2B | 74,000 | 1,448 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Hospira | $64,435 | $4.5B | 19,000 | - |
| Halozyme | $93,996 | $1.0B | 136 | 14 |
| Aeras | $52,244 | $39.3M | 72 | - |
Neurocrine Biosciences revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Neurocrine Biosciences highest paying jobs
Zippia gives an in-depth look into the details of Neurocrine Biosciences, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Neurocrine Biosciences. The employee data is based on information from people who have self-reported their past or current employments at Neurocrine Biosciences. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Neurocrine Biosciences. The data presented on this page does not represent the view of Neurocrine Biosciences and its employees or that of Zippia.
Neurocrine Biosciences may also be known as or be related to NEUROCRINE BIOSCIENCES. INC, Neurocrine Biosciences, Neurocrine Biosciences Inc, Neurocrine Biosciences Inc. and Neurocrine Biosciences, Inc.